Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • MAY 2021 Issue has been successfully launched on 1 May 2021.



S.B. Somwanshi*, V.B. More, S.N. Hiremath1, R.T. Dolas, K.B. Kotade,V.M.Gaware


Hemophilia is an inherited bleeding disorder where one of the bloods clotting proteins is absent or present in a reduced amount. People with Hemophilia, do not bleed faster than anyone else; but will bleed continuously at the normal rate until they are treated. Hemophilia has an estimated frequency of approximately one in 10000 births. Estimations based on the World Federation of Haemophilia’s (WFH) annual global surveys indicate that the number of people with Hemophilia in the world is approximately 400000. The history of Hemophilia shows the human mind attempting to define and encompass a mysterious yet fascinating phenomenon; and also the human heart responding to the challenge of repeated adversity. There is obviously a need to establish facilities and treatment options that will help the patient with Hemophilia, to manage their life with ease. As this is a genetic disorder no complete cure is possible as of now. The available treatment for Hemophilia is by replacing the missing clotting factor in the blood through an intravenous infusion of clotting factor concentrate. Several new technologies are also being implemented to advance Hemophilia, treatment. Multiple trials and studies are underway to examine the possibility to use gene therapy to replace the defective genes in Hemophilia. To date, stable and sustained production of the deficient clotting factors has not been achieved in humans, but this is an area of active investigation that holds great promise for the new delivery systems of the existing therapies or new treatment options has to be driven by pharmacy professionals. The present review broadly describes an overview of the management of various aspects of Hemophilia in order to draw the attention of medical as well as pharmacy professionals for the benefit of millions of hemophilic patients.

Keywords: Hemophilia, Clotting factors, Hemostasis, Inheritance, Prophylaxis, Treatment

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More